12:00 AM
 | 
Jan 17, 2000
 |  BC Week In Review  |  Clinical News  |  Regulatory

Aptosyn exisulind regulatory update

CLPA said that the FDA will evaluate its NDA for Aptosyn, a selective apoptosis inducer, to treat familial...

Read the full 70 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >